Intercell AG

euro adhoc: Intercell AG
quarterly or semiannual financial statement
Full year 2007 expected to be profitable - All development programs on track - Strong strategic and financial position due to successful progress in partnerships

@@start.t1@@--------------------------------------------------------------------------------   Disclosure announcement transmitted by euro adhoc. The issuer is responsible   for the content of this announcement. --------------------------------------------------------------------------------@@end@@

6-month report

13.08.2007

Vienna (Austria), August 13, 2007 - Today Intercell AG (VSE: ICLL) announced the financial results for H1 2007 and an update on the company´s development programs and strategy.

Clear strategy to market for the first product - Intercell´s Japanese Encephalitis vaccine

» All clinical studies supporting the licensure applications for US, EU and    Australia completed » US regulatory filing initiated - full BLA submission expected in H2 2007 -    expected approval H1 2008 » Pediatric Phase II clinical trial in India started - results expected for    end 2007

World-leading franchise in Nosocomial Infections

» S.aureus vaccine partnered with Merck&Co - Phase II expected to start in H2    2007 » Pseudomonas vaccine - start of Phase II/III targeting intensive care unit    patients planned for H1 2008

Hepatitis C vaccine - Phase II "proof-of-concept" study

» Interim results of approximately 25 study participants expected for August    2007

Broadening the use of novel vaccine adjuvant - Intercell´s IC31®

» Phase I trial for Influenza vaccine adjuvanted with IC31® started -   recruitment completed - results expected for early 2008

Strategic partnership with Novartis (closed July 2, 2007)

» Intercell to receive EUR 270 million in upfront payments and equity   investment » 4.8 million new shares at a share price of EUR 31.25 » exclusive Partnership for IC31® in influenza vaccines » co-development in HCV therapeutic vaccines » certain options for not-partnered vaccine candidates to Novartis » closing of the transaction expected in Q3 2007

Solid financial and strong strategic position for further growth

» EUR 15.6 million net loss for H1 2007, up 26.7 percent as compared to H1 2006 -  reflecting R&D and manufacturing capacity increase » Strong cash position with EUR 81.1 million in liquid funds at June 30, 2007 » Liquid funds expected to be approximately EUR 300 million at the end of 2007 » Full year 2007 expected to be first profitable year in company history,    based on revenues from technology based strategic product alliances

"According to plan our increased net loss in the first half of 2007 mainly results from higher R&D and manufacturing spending. However, we expect to recognize revenues of approximately EUR 50 million this year. This would make 2007 the first profitable year in the young history of our company. After completion of the recently signed agreement with Novartis, we expect to end the year with a cash balance of approximately EUR 300 million," states Intercell´s CFO Werner Lanthaler.

"Our strategy and highest priority is to maintain and to extend our leading role as most innovative biotech company in the field of vaccines and anti-infective antibodies," states Gerd Zettlmeissl, CEO of Intercell.

The full half-year report is available at the executive offices of Intercell AG, Campus Vienna Biocenter 6, 1030 Vienna or at www.intercell.com.

@@start.t2@@end of announcement                                                 euro adhoc 13.08.2007 06:54:04
--------------------------------------------------------------------------------@@end@@

ots Originaltext: Intercell AG
Im Internet recherchierbar: http://www.presseportal.ch

Further inquiry note:
Intercell AG
Mag. Astrid Meinl
Corporate Communications
Tel. +43 1 20620-313
ameinl@intercell.com

Branche: Biotechnology
ISIN:      AT0000612601
WKN:        A0D8HW
Börsen:  Wiener Börse AG / official market



Weitere Meldungen: Intercell AG

Das könnte Sie auch interessieren: